Active	Status	Sponsor type	Region	Phase	Filter
3 Active 20 Inactive 23 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Gamunex (intravenous normal human immunoglobulin 10%) / Bayer, Grifols, Kedrion
NCT06752356: A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Not yet recruiting	3	161	NA	Immune globulin (human) 10% solution for intravenous administration, KIg10	Kedrion S.p.A.	Chronic Inflammatory Demyelinating Polyneuropathy	12/27	12/27
FD-R-03447-02, NCT00644865: Intravenous Gammaglobulin for Sickle Cell Pain Crises	Recruiting	1/2	56	US	Immune Globulin Intravenous, GAMUNEX (Talecris Biotherapeutics)	Shi, Patricia, M.D., Grifols Therapeutics Inc., Food and Drug Administration (FDA), National Heart, Lung, and Blood Institute (NHLBI)	Sickle Cell Anemia	10/12	10/12
NCT01757418: Intravenous Gammaglobulin for Sickle Cell Pain Crises	Recruiting	1/2	300	US	Immune Globulin Intravenous (IVIG), GAMUNEX (Talecris Biotherapeutics), Normal saline, Placebo	Deepa Manwani, Food and Drug Administration (FDA), Case Western Reserve University, Grifols Therapeutics LLC	Sickle Cell Disease, Pain	12/26	12/26